Adding Gedatolisib to Fulvestrant, with or without Palbociclib, Improves PFS in Patients with HR-positive/HER2-negative, PIK3CA Wild-Type ABC By Ogkologos - March 17, 2026 190 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the VIKTORIA-1 study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR Surgical Technique Helps Keep Breast Cancer Patients from Going Under the... September 26, 2019 How My Cancer Diagnosis Has Fueled My Work in Improving Access... December 19, 2023 When Used Together, Chemo and Cardiac Drug Improve Chances of Cancer... December 17, 2021 FDA Approves Fam-Trastuzumab Deruxtecan-nxki for Unresectable or Metastatic HR-positive, HER2-low or... March 6, 2025 Load more HOT NEWS Spectacular Breast Cancer Awareness Calendar Showcases Survivors’ Stories, Told with Body... The Future Front Line: Pre-Med During COVID-19 5 Ways Teens or Young Adults Can Cope With Loneliness During... Incorporating sTILs Into PREDICT Substantially Improves the Model’s Ability to Distinguish...
